Stockscreener 앱 받기
17.75
2.52%
-0.465
전일 마감가:
$18.22
열려 있는:
$17.78
하루 거래량:
2.49M
Relative Volume:
0.64
시가총액:
$13.20B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-17.62
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
-7.64%
1개월 성능:
-17.13%
6개월 성능:
-36.34%
1년 성능:
-11.02%
1일 변동 폭
$17.37
$18.13
1주일 범위
$17.37
$19.34
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.77 | 13.56B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.05 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.88 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.40 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
834.30 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.49 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
What institutional flow reveals about Summit Therapeutics Inc.Swing Trade & Smart Investment Allocation Tips - newser.com
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Trade Signal Summary & Daily Technical Forecast Reports - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
Is Summit Therapeutics Inc. showing signs of accumulation2025 Geopolitical Influence & Stepwise Swing Trade Plans - newser.com
What MACD and RSI say about Summit Therapeutics Inc.2025 Short Interest & Accurate Technical Buy Alerts - newser.com
Can Summit Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Community Consensus Picks - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeMarket Trend Report & Weekly Market Pulse Alerts - newser.com
1 Monster Stock in the Making to Buy and Hold - AOL.com
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Should you hold or exit Summit Therapeutics Inc. now2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 - Business Wire
Applying sector rotation models to Summit Therapeutics Inc.2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Summit Therapeutics (SMMT) Aims for FDA Nod for Ivonescimab in N - GuruFocus
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - Insider Monkey
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
10 Stocks Under $20 to Buy According to Analysts - Insider Monkey
Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders - StreetInsider
Why Wall Street Is Backing These 3 Comeback Stocks - Investing.com
Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance
Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛
Can Summit Therapeutics Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Price Targets & High Return Stock Watch Alerts - newser.com
Allianz Asset Management GmbH Decreases Stock Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.56%
자본화:
|
볼륨(24시간):